Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|December 19, 2022
Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 StudyJeffrey S Dover, Shannon D Humphrey, Z Paul Lorenc, et al.
Ophthalmology|July 24, 2012
Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trialsRohit Varma, Neil M Bressler, Ivan Suñer, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 17, 2020
Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter StudyVince Bertucci, Shannon Humphrey, Jean Carruthers, et al.
JAMA Ophthalmology|May 24, 2013
Reading speed improvements in retinal vein occlusion after ranibizumab treatmentIvan J Suñer, Neil M Bressler, Rohit Varma, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 11, 2020
A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 StudyJeremy B Green, Kavita Mariwalla, Kyle Coleman, et al.
Ophthalmology|April 20, 2010
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyPeter A Campochiaro, Jeffrey S Heier, Leonard Feiner, et al.
Plastic and Reconstructive Surgery|October 15, 2019
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)Jean D Carruthers, Steve Fagien, John H Joseph, et al.
Ophthalmology|July 1, 2011
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III studyPeter A Campochiaro, David M Brown, Carl C Awh, et al.
Ophthalmology|January 29, 2013
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationBrandon G Busbee, Allen C Ho, David M Brown, et al.
Movement Disorders Clinical Practice|July 17, 2018
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter StudyJoseph Jankovic, Daniel Truong, Atul T Patel, et al.
Pageof 4